Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease
In Canada, lecanemab is indicated for the treatment of adult patients with…
LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China
September 28, 2025 19:30 ET Â | Source: Biogen Inc. TOKYO and CAMBRIDGE,…
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the…
